April 14th 2025
Furthermore, C-reactive protein has greater prognosis for lung cancer, colorectal cancer, and ovarian cancer.
Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pha...
July 9, 2025 | 1:00 – 2:00 PM ET
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
The Oncology Pharmacist’s Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enh...
August 12, 2025 | 6:00 PM ET & 8:00 PM ET
View More
Overcoming Disparities in Multiple Myeloma Treatment: Empowering Pharmacists to Drive Change
1.0 Credit / Health Equity, Diversity & Inclusion, Hematologic Cancer, Hematology, Oncology
View More
An American Journal of Managed Care® Forum: Discussing the Expanding Targeted Therapy Options and Complexities...
1.5 Credits / Breast Cancer, Oncology
View More
Navigating Treatment Evolution in Myelofibrosis: Oncology Pharmacist's Strategies for JAK Inhibitor Optimizati...
1.0 Credit / Hematologic Cancer, Hematology, Oncology
View More
Ensuring Pharmacy Technicians’ Proficiency in Risk Evaluation and Mitigation Strategies
1.0 Credit / Law, Pain Management, Opioids
View More
BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatme...
1.0 Credit / Hematologic Cancer, Oncology
View More
The Latest Updates and Pharmacist Perspectives on RET Inhibitors in Non‒Small Cell Lung Cancer
0.5 Credit / Oncology, Lung Cancer
View More
Transforming Small Cell Lung Cancer Management With DLL3-Targeted Therapies
1.0 Credit / Oncology, Lung Cancer
View More
Cytokine Release Syndrome With Bispecific Antibodies: A Pharmacist's Guide to Safe Management
1.0 Credit / Hematologic Cancer, Lung Cancer, Oncology
View More
A Pharmacist's Guide to the Safe and Effective Management of BTK and BCL-2 inhibitors in Chronic Lymphocytic L...
1.0 Credit / Hematologic Cancer, Oncology
View More
How Artificial Intelligence Is Transforming Cancer Care: Essential Insights for Oncology Pharmacists
1.0 Credit / Oncology
View More
Charting the Course: The Pharmacist's Role in Safeguarding Patients From Immune-Related Adverse Events
1.0 Credit / Oncology
View More
Enhancing Endometrial Cancer Management: Highlights of Molecular Insights, Treatment Approaches, and Toxicity ...
1.0 Credit / Gynecologic Cancer, Oncology, Women's Health
View More
Closing Gaps in CLL Care: Managed Care Insights and Strategies
1.5 Credit / Hematologic Cancer, Oncology
View More
Enhancing Safety in Cancer Care: Expert Guidance on Toxicity Management of HER2, TROP2, and HER3-Targeted Anti...
1.0 Credit / Oncology
View More
Advancements in Extensive-Stage Small Cell Lung Cancer Therapy: Integrating Clinical Evidence to Fill Gaps in ...
1.0 Credit / Oncology, Lung Cancer
View More
Guiding Bispecific Antibody Use in Non-Hodgkin Lymphoma: Integrating Evidence and Enhancing Care
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Navigating the New Wave in Targeted Therapies for Acute Myeloid Leukemia: A Focus on IDH and FLT3 Mutations
1.0 Credit / Hematologic Cancer, Oncology
View More
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and...
1.0 Credit / Oncology, Hematology, Hematologic Cancer
View More
Multidisciplinary Perspectives and Patient-Centered Approaches in Newly Diagnosed Multiple Myeloma
1.5 Credits / Hematologic Cancer, Oncology, Hematology
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based R...
1.5 Credits / Hematologic Cancer, Hematology, Oncology
View More
Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management
1.5 Credits / Oncology, Hematology
View More
Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer
1.5 Credits / Breast Cancer, Oncology, Women's Health
View More
Expanding Access to Antibody-Based Regimens in Relapsed/Refractory Multiple Myeloma
1.0 Credits / Oncology
View More
Tracking a Moving Target in HR+ Metastatic Breast Cancer: Innovative Oral Therapies and Evolving Strategies
1.0 Credits / Oncology
View More
An Evolving Treatment Paradigm: Innovative Approaches and Critical Insights in the Management of Newly Diagnos...
1.0 Credits / Oncology
View More
Advancing Care in Metastatic Prostate Cancer Care: Emerging Combination Therapies and Patient-Centered Strateg...
1.0 Credits / Oncology
View More
Mosunetuzumab Evokes Strong Response in Elderly Population With DLBCL
August 26th 2021Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.
Non–CAR T-Based Strategies Shake Up the Management of Non-Hodgkin Lymphoma
August 19th 2021An expert highlights the progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
Melphalan flufenamide (Pepaxto; Oncopeptides AB) in combination with dexamethasone was granted accelerated approval on February 26, 2021, by the FDA for adult patients with relapsed or refractory multiple myeloma.